Ειδήσεις: LIFESCI CAPITAL | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

20/03 08:22 defenseworld.net

Research Analysts Set Expectations for EPRX FY2026 Earnings

Eupraxia Pharmaceuticals FY2026 earnings analyst downgrade Strong‑Buy Strong‑Sell price target

19/03 08:06 defenseworld.net

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded at Lifesci Capital

Tarsus Pharmaceuticals Lifesci Capital Oppenheimer Weiss Ratings Wall Street Zen EPS forecast

19/03 07:16 defenseworld.net

What is Lifesci Capital’s Estimate for Savara Q2 Earnings?

Savara Inc Lifesci Capital Q2 earnings EPS forecast buy rating price target

18/03 11:02 defenseworld.net

Tenax Therapeutics (NASDAQ:TENX) Now Covered by Cantor Fitzgerald

Tenax Therapeutics Cantor Fitzgerald Guggenheim Weiss Ratings Lifesci Capital William Blair

16/03 07:48 defenseworld.net

What is Lifesci Capital’s Forecast for TENX Q1 Earnings?

Tenax Therapeutics Q1 earnings Lifesci Capital strong buy full‑year forecast William Blair

15/03 08:32 defenseworld.net

Prime Medicine (NASDAQ:PRME) Research Coverage Started at Oppenheimer

Prime Medicine PRME Oppenheimer Lifesci Capital analyst ratings outperform

14/03 08:46 defenseworld.net

Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho

Maze Therapeutics Mizuho Lifesci Capital Weiss Ratings BTIG HC Wainwright

14/03 08:46 defenseworld.net

Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho

Maze Therapeutics Mizuho Lifesci Capital Weiss Ratings BTIG HC Wainwright

Loading...